H43
2-[4-[(3S)-3-[[(1R)-1-naphthalen-1-ylethyl]amino]pyrrolidin-1-yl]phenyl]ethanoic acid
| Created: | 2020-11-02 |
| Last modified: | 2021-06-16 |
Find Related PDB Entry |
|---|
Find related ligands: |
|---|
Chemical Details | |
|---|---|
| Formal Charge | 0 |
| Atom Count | 54 |
| Chiral Atom Count | 2 |
| Bond Count | 57 |
| Aromatic Bond Count | 17 |
Chemical Component Summary | |
|---|---|
| Name | 2-[4-[(3S)-3-[[(1R)-1-naphthalen-1-ylethyl]amino]pyrrolidin-1-yl]phenyl]ethanoic acid |
| Synonyms | Evocalcet |
| Systematic Name (OpenEye OEToolkits) | 2-[4-[(3~{S})-3-[[(1~{R})-1-naphthalen-1-ylethyl]amino]pyrrolidin-1-yl]phenyl]ethanoic acid |
| Formula | C24 H26 N2 O2 |
| Molecular Weight | 374.475 |
| Type | NON-POLYMER |
Chemical Descriptors | |||
|---|---|---|---|
| Type | Program | Version | Descriptor |
| SMILES | CACTVS | 3.385 | C[CH](N[CH]1CCN(C1)c2ccc(CC(O)=O)cc2)c3cccc4ccccc34 |
| SMILES | OpenEye OEToolkits | 2.0.7 | CC(c1cccc2c1cccc2)NC3CCN(C3)c4ccc(cc4)CC(=O)O |
| Canonical SMILES | CACTVS | 3.385 | C[C@@H](N[C@H]1CCN(C1)c2ccc(CC(O)=O)cc2)c3cccc4ccccc34 |
| Canonical SMILES | OpenEye OEToolkits | 2.0.7 | C[C@H](c1cccc2c1cccc2)N[C@H]3CCN(C3)c4ccc(cc4)CC(=O)O |
| InChI | InChI | 1.03 | InChI=1S/C24H26N2O2/c1-17(22-8-4-6-19-5-2-3-7-23(19)22)25-20-13-14-26(16-20)21-11-9-18(10-12-21)15-24(27)28/h2-12,17,20,25H,13-16H2,1H3,(H,27,28)/t17-,20+/m1/s1 |
| InChIKey | InChI | 1.03 | RZNUIYPHQFXBAN-XLIONFOSSA-N |
Drug Info: DrugBank
DrugBank data are sourced from datasets licensed under a Creative Common's Attribution-NonCommercial 4.0 International License
| DrugBank ID | DB12388 |
|---|---|
| Name | Evocalcet |
| Groups | investigational |
| Description | Evocalcet has been used in trials studying the treatment of Hyperparathyroidism and Secondary Hyperparathyroidism. |
| Synonyms | Evocalcet |
| Categories |
|
| ATC-Code | H05BX06 |
| CAS number | 870964-67-3 |
Related Resource References
| Resource Name | Reference |
|---|---|
| Pharos | CHEMBL4297621 |
| PubChem | 71242808 |
| ChEMBL | CHEMBL4297621 |














